Xortx TherapeuticsXRTX
13F holders, Q1 2025 (March 31)2holders −4
0new positions
4sold out
$0.92avg. 13F price*
At the end of Q1 2025, 2 institutions reported holding Xortx Therapeutics Inc. (XRTX) in their 13F filings, down 4 from Q4 2024. 0 opened new positions and 4 sold out. The largest holders were Clearstead Advisors, LLC ($266) and National Bank of Canada ($150).
- Company
- Xortx Therapeutics Inc.
- CUSIP
- 98420Q306
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 4 | $322K |
All 13F filers, Q4 2024 → Q1 2025: 286,513 shares sold, net −286,513 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Clearstead Advisors, LLC | 0.00% | No change | 277 | $266 |
| National Bank of Canada | 0.00% | Reduce -89.2% | 174 | $150 |
"% of holder's portfolio" is XRTX's weight in each manager's 13F, not the share of Xortx Therapeutics Inc. the manager owns.